Publicacions en què col·labora amb ISAAC PASCUAL CALLEJA (13)

2024

  1. Retrospective variant reclassification and resequencing in hypertrophic cardiomyopathy: a reference unit centre experience

    European Journal of Preventive Cardiology, Vol. 31, Núm. 6, pp. e38-e41

  2. Survival analysis and gender differences in hypertrophic cardiomyopathy proband patients referred for genetic testing

    International Journal of Cardiology, Vol. 408

2023

  1. Chromosome Y Haplogroup R Was Associated with the Risk of Premature Myocardial Infarction with ST-Elevation: Data from the CholeSTEMI Registry

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  2. Mitochondrial Heteroplasmy as a Marker for Premature Coronary Artery Disease: Analysis of the Poly-C Tract of the Control Region Sequence

    Journal of Clinical Medicine, Vol. 12, Núm. 6

  3. Opportunistic Genetic Screening for Familial Hypercholesterolemia in Heart Transplant Patients

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. KCNH2 p.Gly262AlafsTer98: A New Threatening Variant Associated with Long QT Syndrome in a Spanish Cohort

    Life, Vol. 12, Núm. 4

2021

  1. The APOB polymorphism rs1801701 A/G (p.R3638Q) is an independent risk factor for early-onset coronary artery disease: Data from a Spanish cohort

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 31, Núm. 5, pp. 1564-1568

2020

  1. Characterization of left ventricular non-compaction cardiomyopathy

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-16

  2. Clinical implications and gender differences of kcnq1 p.Gly168arg pathogenic variant in long qt syndrome

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-12

  3. Familial hypercholesterolemia in premature acute coronary syndrome. Insights from cholestemi registry

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-12

  4. IL17RA in early-onset coronary artery disease: Total leukocyte transcript analysis and promoter polymorphism (rs4819554) association

    Cytokine, Vol. 136

2019

  1. Gene variants in the NF-KB pathway (NFKB1, NFKBIA, NFKBIZ) and risk for early-onset coronary artery disease

    Immunology Letters, Vol. 208, pp. 39-43

  2. Insights Into Hypertrophic Cardiomyopathy Evaluation Through Follow-up of a Founder Pathogenic Variant

    Revista Espanola de Cardiologia, Vol. 72, Núm. 2, pp. 138-144